Bessemer Group’s Kite Pharma, Inc. KITE Stock Holding History

Bessemer Group’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-17	Closed	-$1K	–	1550
2016 Q1	$1K	Buy	+17	New	+$823	﹤0.01%	1461

Other funds holding KITE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bessemer Group's KITE Position: Q2 2016 in Review

Bessemer Group sold out of Kite Pharma, Inc. (KITE) in Q2 2016, closing a stake of 17 shares — an estimated $1K sold.

Bessemer Group first reported a position in KITE in Q1 2016 and held it in 1 quarter. The position peaked at $1K in Q1 2016. 173 funds tracked by Wall St. Rank hold KITE as of Q2 2016.

Bessemer Group reported no remaining Kite Pharma, Inc. position as of Q2 2016 after selling out during the quarter.
Bessemer Group sold 17 Kite Pharma, Inc. shares in Q2 2016, an estimated $1K.
Bessemer Group first reported a position in Kite Pharma, Inc. in Q1 2016 and held it in 1 quarter.
Bessemer Group's Kite Pharma, Inc. position peaked at $1K in Q1 2016.
173 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q2 2016.

Based on Bessemer Group's 13F filing for Q2 2016, filed 11 Aug 2016.